CoChat
Sign Up
Cited by 136Liver Disease Diagnosis and TreatmentBariatric Surgery and OutcomesPharmacology and Obesity Treatment

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease

Khoo, Joan, Hsiang, John C., Taneja, Ranu, Koo, Seok‐Hwee, Soon, Gaik‐Hong, Kam, Carmen J., Law, Ngai‐Moh, Ang, Tiing‐Leong·2019·Liver International
DOI 10.1111/liv.14065
Open this paper in CoChat — free account

Abstract

BACKGROUND & AIMS: We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD). METHODS: , 90% male) adults with NAFLD defined as liver fat fraction (LFF) > 5% on magnetic resonance imaging without other causes of hepatic steatosis were randomized to a supervised programme of energy restriction plus moderate-intensity exercise to induce ≥ 5% weight loss (DE group, n = 15), or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks, followed by 26 weeks with only advice to prevent weight regain. RESULTS: Diet and exercise and LI groups had significant (P < 0.01) and similar reductions in weight (-3.5 ± 3.3 vs -3.0 ± 2.2 kg), LFF (-8.1 ± 13.2 vs -7.0 ± 7.1%), serum alanine aminotransferase (-39 ± 35 vs -26 ± 33 U/L) and caspase-cleaved cytokeratin-18 (cCK-18) (-206 ± 252 vs -130 ± 158 U/L) at 26 weeks. At 52 weeks, the LI group significantly (P < 0.05) regained weight (1.8 ± 2.1 kg), LFF (4.0 ± 5.3%) and cCK-18 (72 ± 126 U/L), whereas these were unchanged in the DE group. CONCLUSIONS: Liraglutide was effective for decreasing weight, hepatic steatosis and hepatocellular apoptosis in obese adults with NAFLD, but benefits were not sustained after discontinuation, in contrast with lifestyle modification. Continuing the exercise learned in the structured programme contributed to the maintenance of liver fat reduction.

Overview

Integrity signals

Registry

Crossref · 10.1111/liv.14065

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Cited by

Sorted by citations

Items 101–136 of 136

Related

See all

Metadata

Authors
Khoo, J., Hsiang, J. C., Taneja, R., Koo, S., Soon, G., Kam, C. J., Law, N., & Ang, T.
Affiliations
Changi General Hospital (SG)
Corresponding author
Khoo, Joan
ORCID
Venue
Liver International
Publisher
Wiley
Published
2019-02-24
Volume
39
Issue
5
Pages
941-949
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
DOI
10.1111/liv.14065
OpenAlex
W2913917435
Cited by
136
References
42
Citations by year
2026: 21 · 2025: 28 · 2024: 21 · 2023: 18 · 2022: 18 · 2021: 16 · 2020: 7 · 2019: 7
FWCI
9.13
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Liver International (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Medical Research Council (NMRC/CG/002/2013)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
liraglutide, non-alcoholic fatty liver disease, weight loss, lifestyle modification, caloric restriction, physical activity, GLP-1 receptor agonists, hepatic steatosis, liver fat fraction, hepatocyte apoptosis, caspase-cleaved cytokeratin 18, weight regain, obesity
MeSH terms
Liraglutide, Healthy Lifestyle, Adult, Female, Humans, Hypoglycemic Agents, Liver, Male, Middle Aged, Obesity, Prospective Studies, Singapore, Weight Loss, Exercise, Body Mass Index, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review